Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 29, 2020Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years
-
May 26, 2020- In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone
-
May 14, 2020Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)
-
May 13, 2020- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
-
Apr 3, 2020- Detailed data to be presented at the Revolutionizing Atopic Dermatitis Conference show adding Dupixent to topical corticosteroids improved skin clearance; average overall disease improved by approximately 80%
-
Mar 16, 2020* U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately
-
Mar 2, 2020* Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial
-
Feb 18, 2020- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine
-
Jan 30, 2020- Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threatening disease for which no treatments are approved
-
Jan 28, 2020If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
-
Jan 23, 2020* Synthorx, Inc. is now a fully owned subsidiary of Sanofi
-
Dec 9, 2019- U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic
-
Nov 21, 2019- Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD)
-
Nov 6, 2019*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma
-
Nov 4, 2019* Will be available in fall 2020, in time for the 2020-2021 flu season
-
Oct 9, 2019Add-on payment to provide additional Medicare reimbursement for Medicare patients prescribed Cablivi in eligible hospital inpatient settings
-
Sep 30, 2019- CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel